Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis

Company Overview

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Key Stats

• Today's Range: $3.90 to $4.22
• 50-Day Range: $3.59 to $8.40
• 52-Week Range: $3.50 to $74.00
• Volume: 24,382 shs
• Average Volume: 146,436 shs
• Market Capitalization: $474,810.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $200.00
• Consensus Rating: Buy

Biodexa Pharmaceuticals Stock Analysis - MarketRank™

Biodexa Pharmaceuticals scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Biodexa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Biodexa Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biodexa Pharmaceuticals are expected to grow in the coming year, from ($3.00) to ($2.00) per share.

Price to Book Value per Share Ratio

Biodexa Pharmaceuticals has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

43.70% of the outstanding shares of Biodexa Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Biodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biodexa Pharmaceuticals has recently increased by 225.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biodexa Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Biodexa Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

43.70% of the outstanding shares of Biodexa Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Biodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biodexa Pharmaceuticals has recently increased by 225.00%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for BDRX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biodexa Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.34% of the stock of Biodexa Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 17.51% of the stock of Biodexa Pharmaceuticals is held by institutions.

BDRX Stock Analysis - Frequently Asked Questions

How have BDRX shares performed this year?

Biodexa Pharmaceuticals' stock was trading at $5.55 on January 1st, 2024. Since then, BDRX stock has decreased by 28.1% and is now trading at $3.99.
View the best growth stocks for 2024 here.

How were Biodexa Pharmaceuticals' earnings last quarter?

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) issued its quarterly earnings results on Thursday, September, 10th. The company reported ($1,600.00) earnings per share for the quarter.

When did Biodexa Pharmaceuticals' stock split?

Shares of Biodexa Pharmaceuticals reverse split before market open on Friday, October 4th 2024. The 1-25 reverse split was announced on Thursday, September 19th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Biodexa Pharmaceuticals?

Shares of BDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Biodexa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biodexa Pharmaceuticals investors own include SoundHound AI (SOUN), Dyne Therapeutics (DYN), NVIDIA (NVDA), Viking Therapeutics (VKTX), TRACON Pharmaceuticals (TCON), ASE Technology (ASX) and BigBear.ai (BBAI).

Company Calendar

• Last Earnings: 9/10/2020
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BDRX
• Previous Symbol: LON:MTPH
• CUSIP: N/A
• CIK: 1643918
• Web: www.midatechpharma.com
• Phone: 441235888300
• Fax: N/A
• Employees: 21
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $200.00
• High Stock Price Target: $200.00
• Low Stock Price Target: $200.00
• Potential Upside/Downside: +4,912.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 2.16
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $83,000.00
• Price / Sales: 5.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $42.56 per share
• Price / Book: 0.09

Miscellaneous

• Outstanding Shares: 119,000
• Free Float: 119,000
• Market Cap: $474,810.00
• Optionable: Not Optionable
• Beta: 1.45